Compare Sana Biotechnology Inc (SANA) vs Uranium Energy Corp (UEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs Uranium Energy Corp — how do they compare? Sana Biotechnology Inc trades at $3.17 (market cap $873.84M), while Uranium Energy Corp trades at $9.55 (market cap $4.65B). The key difference: Uranium Energy Corp is far larger — about 5.3× Sana Biotechnology Inc's market cap. Which is the better fit depends on your goals.
| SANA | UEC | |
|---|---|---|
Market Cap | $873.84M | $4.65B |
Sector | Health | Energy |
52-Week High | $5.92 | $20.14 |
52-Week Low | $2.68 | $8.00 |
Enterprise Value | $848.03M | $4.16B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $3.14, down 0.32% with bearish technical indicators despite strong analyst support. The company shows significant financial challenges with negative ROE of -147.41% and net income of -$244.17M for 2025, though cash burn improved from -$55M to -$12M in 2026. Recent positive developments include a Zacks upgrade to Buy and groundbreaking clinical data published in NEJM.
Investment outlook remains speculative with high execution risk given substantial losses, but strong analyst consensus (82% Buy ratings) reflects optimism about SANA's innovative cell therapy pipeline. Key risks include continued cash burn and clinical trial outcomes, while potential catalysts include successful product development in diabetes and CAR-T therapies.
UEC trades at $9.40, up 1.29% today, but faces bearish technical signals with 18 sell indicators against 2 buys. The company reported a net loss of $87.66 million in 2025 on $66.84 million revenue, with a negative net margin of -513.24% in 2026. Recent news highlights operational challenges, including zero sales in Q3 2026 and wider losses, though strategic assets and $794 million liquidity offer some stability.
Despite analyst consensus favoring buys (87.5%), high execution risks and persistent losses temper near-term optimism. Investment appeal hinges on successful production ramp-up and uranium price recovery, but volatility and cost pressures present significant downside risks for stockholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About Uranium Energy Corp
Uranium Energy Corp is a leading American uranium mining and exploration company, currently holding the largest resource base and licensed production capacity in the United States. Utilizing low-cost, environmentally friendly In-Situ Recovery (ISR) mining, UEC is a central player in the domestic nuclear fuel supply chain, transitioning from a resource holder to an active producer and refiner to meet the accelerating demand for carbon-free energy.
Read more on UEC →
